Evrysdi Risdiplam Powder for Oral Solution Package Insert

Evrysdi risdiplam powder for oral solution package insert: dosage, administration, contraindications and safety for spinal muscular atrophy (SMA).


Evrysdi Risdiplam Powder for Oral Solution Package Insert - cover page
Brand
Evrysdi
Category
Drugs
Document type
Product Leaflet
Language
Chinese
Pages
36
File format
PDF
File size
1.2 MB
Published
09 November, 2026
Updated
09 November, 2026
MD5 checksum
1499CDCF10EA13A6FC687875FAD17DFF

About this manual

Evrysdi (risdiplam) powder for oral solution is used to treat spinal muscular atrophy (SMA) in patients aged 16 days and older. Each bottle contains 60 mg of risdiplam and is reconstituted by a healthcare professional into an oral solution at 0.75 mg/mL.

The insert gives the once-daily dose by age and body weight, administration with the provided oral syringe, and contraindications for patients allergic to risdiplam or any excipient. It also covers precautions including embryo-fetal toxicity, contraception, and use in pregnancy, breastfeeding, children and older adults. This manual is written in Chinese.

What's inside

  • Indications
  • Dosage and Administration
  • Adverse Reactions
  • Contraindications
  • Precautions
  • Use in Pregnancy and Lactation
  • Pediatric Use
  • Geriatric Use
  • Drug Interactions
  • Ingredients

Specifications

Content per bottle60 mg risdiplam
Molecular formulaC22H23N7O
Molecular weight401.46
Reconstituted concentration0.75 mg/mL

Frequently asked questions

What is Evrysdi used for?

It treats spinal muscular atrophy (SMA) in patients aged 16 days and older.

How is the daily dose determined?

The recommended dose depends on age and body weight.

Who must not take this medicine?

It is contraindicated in patients known to be allergic to risdiplam or any excipient.

Can it be used during pregnancy?

Pregnant women should not use risdiplam during pregnancy unless the benefit to the mother outweighs the potential risk to the fetus.

Download PDF (1.2 MB)